Submit to Special Issue Submit Abstract to Special Issue Review for Animals Edit a Special Issue

Journal Browser

► Journal Browser

Special Issue "Recent Advances in Canine Mammary Tumors"

Print Special Issue Flyer
Special Issue Editors
Special Issue Information
Keywords
Published Papers

A special issue of Animals (ISSN 2076-2615). This special issue belongs to the section "Companion Animals".

Deadline for manuscript submissions: 30 June 2023 | Viewed by 3758

Share This Special Issue

Special Issue Editors

Prof. Dr. Debora Aparecida Pires de Campos Zuccari

E-Mail Website
Guest Editor

Laboratório de Investigação Molecular no Câncer (LIMC), Faculdade de Medicina de São José do Rio Preto (FAMERP), Avenida Brigadeiro Faria Lima, 5416, São José do Rio Preto 15090-000, Brazil
Interests: immunohistochemical evaluation of mammary cancer biomarkers; tumor biomarkers in liquid biopsy; extracellular vesicles as diagnostic and prognostic tools for cancer; antioxidant action of melatonin and its potential use in mammary cancer treatment

Prof. Dr. Luiz Gustavo de Almeida Chuffa

E-Mail Website
Guest Editor

Department of Structural and Functional Biology, Institute of Biosciences of Botucatu, Botucatu 18618-689, Brazil
Interests: effects of melatonin and its MT2/MT2 receptors on cancer cells; potential therapeutic use of melatonin; paclitaxel; P-MAPA immunomodulator associated with interleukin-12 in ovarian cancer

Prof. Dr. Adriana Alonso Novais

E-Mail Website
Guest Editor

Instituto de Ciências da Saúde (ICS), Universidade Federal de Mato Grosso (UFMT), Campo Grande 78550-000, Brazil
Interests: immunohematology; canine blood groups; extracellular vesicles as tumor biomarkers in liquid biopsy and their role as diagnostic and prognostic tools in mammary tumors

Prof. Dr. Guilherme Henrique Tamarindo

E-Mail Website
Guest Editor

Laboratório de Investigação Molecular no Câncer (LIMC), Faculdade de Medicina de São José do Rio Preto (FAMERP), Avenida Brigadeiro Faria Lima, 5416, São José do Rio Preto 15090-000, Brazil
Interests: tumor metabolism and metabolic reprogramming; lipid metabolism in cancer; diet as a preventive and therapeutic approach; mitochondria in cancer, tumor immunology and comparative oncology

Special Issue Information

Dear Colleagues,

Canine mammary tumors (CMTs) are the most common neoplasm in intact female dogs, and about 50% of them are considered malignant. A CMT is a good spontaneous animal model of human breast cancer (HBC) research because it shares many similarities, such as epidemiologic, clinical, genetical, biological and pathological characteristics; additionally, their histological and molecular patterns are very heterogeneous. Different hormones and growth factors influence the occurrence of CMTs, but the pathological mechanisms remain unclear. In addition to circulating hormones, their receptors play a central role in mammary tumor formation (estrogen and progesterone receptors). Surgery is still the frontline treatment, but other therapies can be beneficial regarding patients’ survival. Advances in molecular pathways associated with cancer progression have highlighted several aspects in the field, and the development of new treatments may be promising for comparative and translational oncology.

This Special Issue aims to publish original research papers or reviews about canine mammary tumors, concerning their diagnosis, prognosis and therapeutics.

Areas of interest: CMT histological and molecular classification for diagnosis and prognosis; biomarkers; therapeutic approaches; experimental models suitable for CMTs; angiogenesis; metastasis and invasion; the role of the immune system and molecular pathways associated with CMT development and progression; and comparative and translational oncology.

We invite you to share your recent findings through this Special Issue.

Prof. Dr. Debora Aparecida Pires de Campos Zuccari
Prof. Dr. Luiz Gustavo de Almeida Chuffa
Prof. Dr. Adriana Alonso Novais
Prof. Dr. Guilherme Henrique Tamarindo
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Animals is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

dogs
cancer
biomarkers
diagnosis
prognosis
extracellular vesicles
therapeutics
liquid biopsy
comparative oncology
translational models

Published Papers (5 papers)

Download All Papers

Research

Open AccessArticle

Parameters of Metabolic Response to Surgical Trauma Induced via Unilateral Total Mastectomy Associated or Not to Ovariohysterectomy in Dogs

Sabrina Marin Rodigheri

Felipe Noleto de Paiva

Bruna Fernanda Firmo

Taise Fuchs

Cynthia Bueno Mani

and

Andrigo Barboza de Nardi

Animals 2023, 13(5), 926; https://doi.org/10.3390/ani13050926 - 03 Mar 2023

Viewed by 445

Abstract

Surgical excision of solid tumors is required for local control of neoplasms. However, surgical trauma can stimulate the release of proangiogenic growth factors, suppressing cell-mediated immunity and favoring the development of micrometastases and progression of residual disease. The present study aimed to evaluate the intensity of the metabolic response to trauma induced via unilateral mastectomy in bitches with mammary neoplasia, the consequences of its joint performance with ovariohysterectomy, and their respective effects on the organic response. Two groups of animals were evaluated in seven perioperative moments, namely, unilateral mastectomy (G1) and unilateral mastectomy associated with ovariohysterectomy (G2). Thirty-two female dogs were selected, ten clinically healthy, and twenty-two diagnosed with mammary neoplasia. Surgical trauma reduced serum concentrations of albumin and interleukin-2 but increased blood levels of glucose and interleukin-6 in the postoperative of G1 and G2 patients. Moreover, serum cortisol levels increased after unilateral mastectomy associated with ovariohysterectomy. Our findings allowed us to conclude that unilateral mastectomy induces significant metabolic alterations in female dogs with mammary neoplasms and its joint performance with ovariohysterectomy increases the organic response to trauma. Full article

(This article belongs to the Special Issue Recent Advances in Canine Mammary Tumors)

► Show Figures

Figure 1

Open AccessArticle

Confirmation of the Prognostic Value of Foxp3+ Cells in Canine Mammary Tumors

and

Animals 2023, 13(3), 505; https://doi.org/10.3390/ani13030505 - 31 Jan 2023

Viewed by 486

Abstract

Foxp3+ cell counts were evaluated by immunohistochemistry in 59 canine mammary tumors, 20 adenomas, and 39 carcinomas in three different compartments: intratumoral, within the adjacent stroma, and in the distant stroma. Foxp3+ lymphocyte counts were compared with histotype, grading, presence of lymphatic invasion, immunohistochemical expression of estrogen and progesterone receptors, expression of c-erbB-2, and the overall survival (OS). Our findings confirmed that Foxp3+ cells were significantly higher in canine mammary carcinomas compared to adenomas. A significantly higher number of Foxp3+ cells were detected in grade III carcinomas compared to grade II carcinomas, as well as in tumors with lymphatic invasion and loss of ER-expression. Finally, a high number of Foxp3+ cells was associated with poor prognosis. In conclusion, our findings highlighted the association of Foxp3+ lymphocytes with negative clinicopathological features and shorter overall survival (OS), thus confirming the role of Tregs as a negative prognostic marker in canine mammary carcinomas. Full article

(This article belongs to the Special Issue Recent Advances in Canine Mammary Tumors)

► Show Figures

Figure 1

Open AccessArticle

Proof-of-Concept Study of an Alpha-Fetoprotein-Derived Peptide for the Management of Canine Mammary Cancer

James A. Bennett

Ann Hohenhaus

and

Thomas T. Andersen

Animals 2023, 13(3), 403; https://doi.org/10.3390/ani13030403 - 25 Jan 2023

Viewed by 503

Abstract

Novel, well-tolerated drugs are needed for the management of canine mammary cancer. Many of these cancers are promoted in their growth by estrogen. Alpha-fetoprotein (AFP) is a ubiquitous mammalian protein that has anti-estrogenic properties. AFPep (the anti-estrogenic site of AFP) has been developed into a readily synthesizable drug. AFPep has been shown to have anti-mammary cancer activity in several models of this disease, both in cell culture and in rodents. The purpose of the study reported herein was to determine the tolerability of AFPep in normal and tumor-bearing dogs. AFPep was given to dogs via both parenteral and oral routes in a single application and in repeated daily doses. Full clinical chemistry and hematology values were determined before and after drug administration. Blood levels of the drug were achieved in dogs that had been previously found to be oncostatic in rodents. No changes in clinical chemistry, hematology, and clinical behaviors were found in dogs following drug administration. The data support the further development of AFPep for clinical use against canine mammary cancer. Full article

(This article belongs to the Special Issue Recent Advances in Canine Mammary Tumors)

Open AccessArticle

Pharmacokinetics of Carboplatin in Combination with Low-Dose Cyclophosphamide in Female Dogs with Mammary Carcinoma

Marília Carneiro Machado

Priscila Akemi Yamamoto

Leandro Francisco Pippa

Natália Valadares de Moraes

Fabiane Maria Fernandes Neves

Ricardo Dias Portela

Stella Maria Barrouin-Melo

Anna Hielm-Björkman

Ana Leonor Pardo Campos Godoy

and

Alessandra Estrela-Lima

Animals 2022, 12(22), 3109; https://doi.org/10.3390/ani12223109 - 10 Nov 2022

Viewed by 956

Abstract

This prospective study aimed to evaluate the effect of metronomic cyclophosphamide on carboplatin’s tolerability, efficacy, and pharmacokinetics in dogs with mammary carcinoma. Sixteen female dogs with mammary carcinoma were divided into groups: 300 mg/m² intravenous (i.v.) carboplatin therapy (G1 = 8) or 300 mg/m² i.v. carboplatin which was associated with 12.5 mg/m² oral cyclophosphamide in a metronomic regimen (G2 = 8). The investigated animals underwent a clinical evaluation, a mastectomy, a carboplatin chemotherapy, and serial blood sampling for the pharmacokinetic analysis. The adverse events and survival rates were monitored. A non-compartmental analysis was applied to calculate the pharmacokinetic parameters of carboplatin in the 2nd and 4th chemotherapy cycles. Carboplatin PK showed high interindividual variability with a 10-fold variation in the area under the plasma concentration–time curve (AUC) in G1. The systemic plasma exposure to carboplatin was equivalent in both of the treatments considering the AUC and maximum plasma concentration (C_max) values. Although the red blood cells (p < 0.0001), platelets (p = 0.0005), total leukocytes (p = 0.0002), and segmented neutrophils (p = 0.0007) were reduced in G2, the survival rate increased (p = 0.0044) when it was compared to G1. In conclusion, adding low daily doses of cyclophosphamide to a carboplatin therapy showed promising outcomes in female dogs with mammary tumors. Full article

(This article belongs to the Special Issue Recent Advances in Canine Mammary Tumors)

► Show Figures

Figure 1

Open AccessArticle

The Analysis of E-Cadherin, N-Cadherin, Vimentin, HER-2, CEA, CA15-3 and SF Expression in the Diagnosis of Canine Mammary Tumors

and

Animals 2022, 12(21), 3050; https://doi.org/10.3390/ani12213050 - 06 Nov 2022

Viewed by 808

Abstract

Canine mammary tumors (CMTs) are one of the most common tumors in female dogs, and they are associated with a poor prognosis owing to their high rate of recurrence and metastasis rates, which make their diagnosis especially important in clinical veterinary medicine. In this study, the characteristics of tumors were observed in dogs suffering from CMTs, and clinical diagnosis and histopathology were used to identify tumors. Furthermore, the expression levels of tumor markers for CMTs were analyzed by enzyme-linked immunosorbent assay (ELISA) and quantitative PCR (qPCR). Upon clinical examination, dogs with CMTs displayed a distinct and irregular mass in the mammary gland, and X-ray (Latero-lateral and ventro-dorsal views) and ultrasonography of the abdomen revealed a moderately echogenic mass at the mammary gland with slightly stronger density than the surrounding tissue. A total of 30 tumors were identified by histopathology, 11 benign and 19 malignant. Changes in some indicators in dogs suffering from CMTs and healthy dogs suggested that there were multiple direct or paraneoplastic changes associated with tumors that could be detected/suspected by hematological examination, and ELISA revealed the HER-2 serum concentrations were significantly different between healthy animals and those with malignant tumors. qPCR indicated that tumor markers N-cadherin, Vimentin, HER-2, CEA, CA15-3 and SF were higher in dogs with malignant tumors than healthy dogs, with a low level of E-cadherin in malignant tumors. This study verified that serological tests and molecular biological tests were essential to the early diagnosis, treatment and prognosis of dogs with tumors. Full article

(This article belongs to the Special Issue Recent Advances in Canine Mammary Tumors)

► Show Figures

Figure 1

Journal Menu

Journal Browser

Special Issue "Recent Advances in Canine Mammary Tumors"

Share This Special Issue

Special Issue Editors

Special Issue Information

Keywords

Published Papers (5 papers)

Research

Further Information

Guidelines

MDPI Initiatives

Follow MDPI